These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32194014)

  • 1. An interdisciplinary review of digital technologies to facilitate anti-corruption, transparency and accountability in medicines procurement.
    Mackey TK; Cuomo RE
    Glob Health Action; 2020; 13(sup1):1695241. PubMed ID: 32194014
    [No Abstract]   [Full Text] [Related]  

  • 2. The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk.
    Kohler JC; Dimancesco D
    Glob Health Action; 2020; 13(sup1):1694745. PubMed ID: 32194011
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches.
    Vian T
    Glob Health Action; 2020; 13(sup1):1694744. PubMed ID: 32194010
    [No Abstract]   [Full Text] [Related]  

  • 4. A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain.
    Saeed G; Kohler JC; Cuomo RE; Mackey TK
    Expert Opin Drug Saf; 2022 Aug; 21(8):1061-1088. PubMed ID: 35714366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review.
    Griffore KA; Bowra A; Guilcher SJT; Kohler J
    Global Health; 2023 Nov; 19(1):91. PubMed ID: 38001483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions to reduce corruption in the health sector.
    Gaitonde R; Oxman AD; Okebukola PO; Rada G
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008856. PubMed ID: 27528494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recalibrating the anti-corruption, transparency, and accountability formula to advance public health.
    Wierzynska A; Steingrüber S; Oroxom R; Bauhoff S
    Glob Health Action; 2020; 13(sup1):1701327. PubMed ID: 32194013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
    Kohler JC; Bowra A
    Global Health; 2020 Oct; 16(1):101. PubMed ID: 33081805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of existing and emerging digital technologies to combat the global trade in fake medicines.
    Mackey TK; Nayyar G
    Expert Opin Drug Saf; 2017 May; 16(5):587-602. PubMed ID: 28349715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (UNCAC) Compliance.
    Wong A; Perehudoff K; Kohler JC
    Glob Public Health; 2024 Jan; 19(1):2350649. PubMed ID: 38752422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-corruption in global health systems: using key informant interviews to explore anti-corruption, accountability and transparency in international health organisations.
    Gorodensky A; Bowra A; Saeed G; Kohler J
    BMJ Open; 2022 Dec; 12(12):e064137. PubMed ID: 36549737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing transparency and accountability in national pharmaceutical systems.
    Paschke A; Dimancesco D; Vian T; Kohler JC; Forte G
    Bull World Health Organ; 2018 Nov; 96(11):782-791. PubMed ID: 30455533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting anti-corruption, transparency and accountability in the recruitment and promotion of health workers to safeguard health outcomes.
    Kirya MT
    Glob Health Action; 2020; 13(sup1):1701326. PubMed ID: 32194012
    [No Abstract]   [Full Text] [Related]  

  • 14. An exploration of anti-corruption and health in international organizations.
    Bowra A; Saeed G; Gorodensky A; Kohler JC
    PLoS One; 2022; 17(8):e0269203. PubMed ID: 35917329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Global Fund: why anti-corruption, transparency and accountability matter.
    Chang Z; Rusu V; Kohler JC
    Global Health; 2021 Sep; 17(1):108. PubMed ID: 34537059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sustainable development goals as a framework to combat health-sector corruption.
    Mackey TK; Vian T; Kohler J
    Bull World Health Organ; 2018 Sep; 96(9):634-643. PubMed ID: 30262945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital technology for health sector governance in low and middle income countries: a scoping review.
    Holeman I; Cookson TP; Pagliari C
    J Glob Health; 2016 Dec; 6(2):020408. PubMed ID: 27648255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-corruption, Transparency and Accountability: Case Study of Healthcare in the Arab Countries.
    Hunter M; Uwaydah Mardini R; El-Seblani A; Elsayed S
    Glob Health Action; 2020; 13(sup1):1704529. PubMed ID: 32194015
    [No Abstract]   [Full Text] [Related]  

  • 19. Public sector reforms and their impact on the level of corruption: A systematic review.
    Mugellini G; Della Bella S; Colagrossi M; Isenring GL; Killias M
    Campbell Syst Rev; 2021 Jun; 17(2):e1173. PubMed ID: 37131927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
    Nsimba SE
    East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.